M T Bertero

Summary

Affiliation: Institute for Cancer Research and Treatment
Country: Italy

Publications

  1. ncbi request reprint Risk assessment in patients with antiphospholipid antibodies
    M Bertero
    Clinical Immunology AO Ordine Mauriziano, Turin, Italy
    Minerva Med 104:639-48. 2013
  2. doi request reprint Primary prevention in antiphospholipid antibody carriers
    M T Bertero
    Clinical Immunology, AO Ordine Muriziano, Torino, Italy
    Lupus 21:751-4. 2012
  3. doi request reprint Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): demographic features, risk factors, clinical and laboratory profile
    M T Bertero
    Immunologia Clinica, AO Ordine Mauriziano, Italy
    Lupus 21:806-9. 2012
  4. doi request reprint Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort
    M Bazzan
    Haematology and Thrombosis Unit, Department of Rare, Immunologic, Hematologic Diseases and Transfusion Medicine, Giovanni Bosco Hospital, Turin, Italy
    Autoimmun Rev 12:826-31. 2013
  5. doi request reprint Neonatal lupus in triplet pregnancy of a patient with undifferentiated connective tissue disease evolving to systemic lupus erythematosus
    M Demaestri
    Master Malattie Rare, Universita degli Studi di Torino, Turin, Italy
    Lupus 18:368-71. 2009
  6. ncbi request reprint The possible role of autoimmunity in the pathogenesis of diabetes in B-thalassemia major
    L Monge
    UOA Diabetologia, AO S Giovanni Battista di Torino, Torino, Italy
    Diabetes Metab 27:149-54. 2001

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Risk assessment in patients with antiphospholipid antibodies
    M Bertero
    Clinical Immunology AO Ordine Mauriziano, Turin, Italy
    Minerva Med 104:639-48. 2013
    ..We look forward to the publication of recommendations of the leading experts in the field, developed during the recent 14th International Congress in Rio de Janeiro, Brazil. ..
  2. doi request reprint Primary prevention in antiphospholipid antibody carriers
    M T Bertero
    Clinical Immunology, AO Ordine Muriziano, Torino, Italy
    Lupus 21:751-4. 2012
    ..Chronic thromboprophylaxis with low-dose aspirin and hydroxychloroquine in aPL positive SLE patients should be prescribed both to prevent thrombosis and to avoid early organ damage...
  3. doi request reprint Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): demographic features, risk factors, clinical and laboratory profile
    M T Bertero
    Immunologia Clinica, AO Ordine Mauriziano, Italy
    Lupus 21:806-9. 2012
    ..This consortium represents an instrument by which to audit clinical practice, to provide counselling to local centres and to sustain future basic and clinical APS research...
  4. doi request reprint Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort
    M Bazzan
    Haematology and Thrombosis Unit, Department of Rare, Immunologic, Hematologic Diseases and Transfusion Medicine, Giovanni Bosco Hospital, Turin, Italy
    Autoimmun Rev 12:826-31. 2013
    ..Moreover, there are evidences that high risk (mainly for aPL profile) APS vascular patients have a high recurrence rate in spite of correct OAT treatment. Clinical trials in this clinical setting are needed...
  5. doi request reprint Neonatal lupus in triplet pregnancy of a patient with undifferentiated connective tissue disease evolving to systemic lupus erythematosus
    M Demaestri
    Master Malattie Rare, Universita degli Studi di Torino, Turin, Italy
    Lupus 18:368-71. 2009
    ..The only manifestation of neonatal lupus we observed in the three newborns was SSA positivity associated with asymptomatic transient neutropenia...
  6. ncbi request reprint The possible role of autoimmunity in the pathogenesis of diabetes in B-thalassemia major
    L Monge
    UOA Diabetologia, AO S Giovanni Battista di Torino, Torino, Italy
    Diabetes Metab 27:149-54. 2001
    ..6%)...